Advertisement

Topics

Uveal Melanoma Pipeline Review, H2 2017 [Report Updated: 10102017] Prices from USD $2000

14:46 EST 13 Nov 2017 | BioPortfolio Reports

Uveal Melanoma Pipeline Review, H2 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveal Melanoma Pipeline Review, H2 2017, provides an overview of the Uveal Melanoma Oncology pipeline landscape.


Uveal melanoma, the most common intraocular tumor, is a disease in which cancer malignant cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include dark spot on the iris, glaucoma, eye pain and eye redness. Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. Treatment includes surgery, radiation and proton therapy.


Report Highlights


Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveal Melanoma Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Uveal Melanoma Oncology, complete with analysis by stage of development, drug target, mechanism of action MoA, route of administration RoA and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.


The Uveal Melanoma Oncology pipeline guide also reviews of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 9, 8, 1 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 1 and 1 molecules, respectively.


Uveal Melanoma Oncology pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The pipeline guide provides a snapshot of the global therapeutic landscape of Uveal Melanoma Oncology.

The pipeline guide reviews pipeline therapeutics for Uveal Melanoma Oncology by companies and universities/research institutes based on information derived from company and industryspecific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, RD brief, MoA other developmental activities.

The pipeline guide reviews key companies involved in Uveal Melanoma Oncology therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Uveal Melanoma Oncology therapeutics based on mechanism of action MoA, drug target, route of administration RoA and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Uveal Melanoma Oncology


Reasons to buy


Procure strategically important competitor information, analysis, and insights to formulate effective RD strategies.

Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Uveal Melanoma Oncology.

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Uveal Melanoma Oncology pipeline depth and focus of Indication therapeutics.

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.

Original Article: Uveal Melanoma Pipeline Review, H2 2017 [Report Updated: 10102017] Prices from USD $2000

NEXT ARTICLE

More From BioPortfolio on "Uveal Melanoma Pipeline Review, H2 2017 [Report Updated: 10102017] Prices from USD $2000"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Melanoma
Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...